By Drug Target Review2024-01-02T16:00:56
Using tumour organoids, researchers have found a starting point for the development of a more refined PDAC drug.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-03-31T14:05:00Z
2026-03-27T13:06:00Z
2023-02-13T11:57:11
Sponsored by Agilent
2024-03-08T10:00:25
Sponsored by Molecular Devices
2025-04-22T14:58:00
Sponsored by Takara Bio USA
2023-06-13T13:30:40
Sponsored by NanoTemper Technologies
Site powered by Webvision Cloud